GRAIL, Inc. reported $165M of revenue over the trailing twelve months, +23% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $165M (to Q2 2026). Net Income: −$392M, trailing twelve months to Q2 2026. Free Cash Flow: −$296M, trailing twelve months to Q2 2026. Op Margin: −338%, trailing twelve months to Q2 2026.

GRALGRAIL, Inc.

HealthcareUSD

$79.59

$31.4252 weeks$116.06

GRAL as reported

GRAIL, Inc. reported $165M of revenue over the trailing twelve months, +23% on the year before. 8 reported series are charted on this page, each one as filed.

$165M

Revenue, trailing twelve months · to Q2 2026 · +23% against the twelve months before

Net Income: −$392M
Net Income · −12% year on year · trailing twelve months to Q2 2026
Free Cash Flow: −$296M
Free Cash Flow · −20% year on year · trailing twelve months to Q2 2026
Op Margin: −338%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for GRAL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$165M	+23%	Q2 2026
Net Income	−$392M	−12%	Q2 2026
EPS	−$9.69	−20%	Q2 2026
Op Margin	−338%	n/a	Q2 2026
Net Margin	−237%	n/a	Q2 2026
ROE	−16%	n/a	Q2 2026
ROA	−14%	n/a	Q2 2026
Free Cash Flow	−$296M	−20%	Q2 2026